Home › Neuroendocrine Carcinoma › Washington › Seattle
Neuroendocrine Carcinoma clinical trials in Seattle, WA
5 studies for Neuroendocrine Carcinoma are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
RecruitingPhase 1
- University of Washington/Fred Hutchinson Cancer Center, Seattle
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RecruitingPhase 1
- Fred Hutch Cancer Center, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
- Fred Hutch Cancer Center, Seattle
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RecruitingPhase 1/2
- Swedish Cancer Institute, Seattle
Neuroendocrine Carcinoma trials in other cities
- Houston, TX6 studies
- New York City, NY5 studies
- Washington, DC4 studies
- Los Angeles, CA4 studies
- Dallas, TX4 studies
- Arlington, VA4 studies
- St. Louis, MO4 studies
- Nashville, TN3 studies
- Columbus, OH3 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.